Pharmaceuticals, Biotechnology and Life Sciences
Data from Phase 2 open-label extension trial of mavorixafor in WHIM syndrome to be presented at the Virtual Edition of…
– MGTA-117 ADC clinical candidate for immune and blood system reset has demonstrated broad therapeutic index; on track for initial…
ADX-629 Expected to Begin Phase 2 Clinical Trials in COVID-19 Respiratory Compromise, Atopic Asthma, and Psoriasis in 2020 Type C…
Progress on novel coronavirus vaccine (mRNA-1273) includes FDA clearance to proceed with Phase 2 study Finalizing protocol for Phase 3…
— Announced Positive Results from STRIDE 3 Clinical Trial of EYSUVIS in March 2020, Demonstrating Statistically Significant Results for Primary…
– First-Quarter Revenue of $707.1 Million – – First-Quarter GAAP Earnings per Share of $1.02 and Non-GAAP Earnings per Share…
– First-Quarter Revenue of $707.1 Million – – First-Quarter GAAP Earnings per Share of $1.02 and Non-GAAP Earnings per Share…
Three oral presentations accepted on new clinical and preclinical data at the American Society of Gene and Cell Therapy (ASGCT)…
Gvoke™ Pre-Filled Syringe (PFS) net sales of $1.7 million in Q1 2020 Gvoke HypoPen™ on track for planned launch in…
WILLIAMSVILLE, N.Y.–(BUSINESS WIRE)–22nd Century Group, Inc. (NYSE American: XXII) (“22nd Century” or “the Company”), a leading plant biotechnology company focused…